Prosidion Limited

Other

Osi Pharmaceuticals, Inc.

Gerard Hugh Thomas

Stuart Edward Bradley

Martin James Procter

Matthew Colin Thor Fyfe

Thomas Martin Krulle

Robert John Rowley

Karen Lesley Schofield

Colin Peter Sambrook Smith

Chrystelle Marie Rasamison

Peter John Murray

Vilasben Kanji Shah

Lisa Sarah Gardner

William Gattrell

Lisa Sarah Bertram

John King-Underwood

Revathy Perpetua Jeevaratnam

Ana Valdesabril

Ana Valdes

Peter John c/o Patents Department Murray

Compounds of Formula (I), R-A-V&#x2014;B&#x2014;R; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.

Heterocyclic derivatives as GPCR receptor agonists

Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes. 

G-protein coupled receptor agonists

Compounds of formula (I): R-A-V&#x2014;B&#x2014;R, wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists

Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase

Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth. 

Pyrrolopyridine-2-carboxylic acid hydrazides

Growing community of inventors

Oxford, United Kingdom

Gerard Hugh Thomas